Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

L0702000

Lisinopril dihydrate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Lisinopril, (S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C21H31O5N3 · 2H2O
Numéro CAS:
83915-83-7
Poids moléculaire :
441.52
Numéro MDL:
MFCD01698825
Code UNSPSC :
41116107
ID de substance PubChem :
329817371
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

lisinopril

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

Clé InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Informations sur le gène

human ... ACE(1636)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lisinopril dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

Angiotensin converting enzyme (ACE) inhibitor.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1368609

Lisinopril, United States Pharmacopeia (USP) Reference Standard

Y0001234

Lisinopril impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001701

Lisinopril for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001709

Lisinopril for system suitability A, European Pharmacopoeia (EP) Reference Standard

1368610

Lisinopril Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP695

Lisinopril dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360D,H373

Classification des risques

Repr. 1A - STOT RE 2

Organes cibles

Kidney

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Captopril ≥98% (HPLC), powder

Sigma-Aldrich

C4042

Captopril

Sarah J Trenfield et al.
International journal of pharmaceutics, 577, 119066-119066 (2020-01-27)
Three-dimensional printing (3DP) is a revolutionary technology in pharmaceuticals, enabling the personalisation of flexible-dose drug products and 3D printed polypills (polyprintlets). A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying
Zhongchao Ma et al.
Human cell, 33(2), 330-336 (2020-01-19)
Renal fibrosis is a common characteristic of chronic kidney disease (CKD), and it can lead to end-stage renal disease. It has been reported that silibinin or lisinopril (MK-521) can inhibit the progression of renal fibrosis. However, the effect of combination
Manal Eid et al.
Journal of separation science, 40(18), 3646-3654 (2017-07-20)
We present an environmentally friendly method for the analysis of three angiotensin-converting enzyme inhibitors and hydrochlorothiazide simultaneously using a green micellar eluent for the first time. The chromatographic separation of enalapril maleate, lisinopril dihydrate, benazepril hydrochloride, and hydrochlorothiazide was implemented
C Valenzuela et al.
General pharmacology, 25(5), 825-832 (1994-09-01)
1. The effects of lisinopril, an angiotensin-converting enzyme inhibitor, were studied on cardiac contractile force, action potential characteristics and membrane ionic currents. 2. In guinea-pig atria, lisinopril (0.001-1 microM) exerted a negative inotropic effect which was accompanied by a shortening
Marinka Baričević et al.
Wiener klinische Wochenschrift, 125(13-14), 408-411 (2013-06-25)
Drug-induced lesions of oral mucosa are well-established side effect of different commonly used drugs. A female patient under treatment for hypertension with an angiotensin-converting enzyme inhibitor (ACE inhibitor), lisinopril, developed blisters and ulcerations on oral mucosa 3 weeks after lisinopril
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique